Liver Diseases in PLWH
Epidemiological Investigation of HIV-infected Patients Complicated With Liver Disease in Zhejiang Province
In Highly Active Antiretroviral Therapy era, fatty liver has become an important cause of liver function damage in people living with HIV (PLWH). There are a large number of PLWH in China who are infected with hepatitis B virus and hepatitis C virus. HIV, hepatitis B virus, hepatitis C virus, drugs, alcohol, etc. affect each other, which makes the cause, diagnosis, and treatment of liver function damage in PLWH complicated in China.
The investigators plan to conduct a large-scale questionnaire survey among PLWH in Zhejiang Province to assess liver function, detect liver Injuries early, and analyze HIV, hepatitis B virus, hepatitis C virus, anti-HIV drugs, alcohol and other factors associate with liver injuries in PLWH, to provide basis for the treatment and prevention of liver disease in PLWH in eastern China.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Biao Zhu, PhD.
- Phone Number: +86 13906535457
- Email: zhubiao1207@zju.edu.cn
Study Contact Backup
- Name: Yongzheng Guo, MD.
- Phone Number: +86 13645814389
- Email: ggyongzheng08@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- The First Affiliated Hospital of Zhejiang University school of medicine
-
Contact:
- Yongzheng Guo, MD
- Phone Number: +86 13645814389
- Email: ggyongzheng08@zju.edu.cn
-
Contact:
- Biao Zhu, PhD
- Phone Number: +86 13906535457
- Email: zhubiao1207@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years old;
- Non-hospitalized patients diagnosed with HIV infection;
- Sign the informed consent voluntarily.
Exclusion Criteria:
- Severe active infection requiring parenteral antibiotics or antifungal treatment within 30 days before the assessment;
- Other major chronic diseases that may affect health-related quality of life, such as extrahepatic malignant tumors;
- Psychotic patients, patients with severe cognitive or neurological deficits;
- Women during pregnancy and lactation;
- Those who refuse to sign informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of liver disease in PLWH
Time Frame: 2020-12-31
|
The overall prevalence of liver disease in PLWH and the prevalence of hepatitis B, C, and fatty liver
|
2020-12-31
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ZJHIVER
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
NCT07122700RecruitingLiver Fat | Cirrhosis, Liver | Liver Fibrosis | NASH | Liver Inflammation | Metabolic Associated Fatty Liver Disease | Liver Steatoses | Metabolic Associated Steatotic Liver Disease
-
NCT06111859RecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With Fibrosis
-
NCT07053488RecruitingLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Metastases | Liver Cancer | Liver Transplant Rejection | Liver Steatoses
-
NCT07519057RecruitingEnd Stage Liver Disease | Liver Transplantation | Liver Transplant | Liver Transplant Surgery
-
NCT06615934Not yet recruitingLiver Transplant; Complications | Liver Transplant Disorder | End-stage Liver Disease
-
NCT07613827Enrolling by invitationLiver Steatosis | Liver Fibrosis | Liver Fibrosis Progression in Chronic Liver Disease | Steatotic Liver Disease | Steatotic Liver Disease of Mixed Origin (MetALD)
-
NCT02719210Completed
-
NCT04107883UnknownLiver Transplantation | End Stage Liver DIsease
-
NCT03748511TerminatedPatients With Fatty Liver Disease